Head and Neck Cancer

Interim Phase II Combination Therapy Results Reported

Published in Cancer Weekly, December 7th, 1998

Onyx Pharmaceuticals, Inc., Richmond, California, reported encouraging interim efficacy data from a Phase II, human clinical trial combining the anticancer viral therapeutic, ONYX-015, with two chemotherapeutic drugs, Cisplatin and 5-FU, in patients with recurrent head and neck cancer.

The company reported higher tumor response rates and duration of response with this therapy than that expected with chemotherapy alone.

"We are pleased with both the response rate and the durability we have seen to date in this study," said Hollings Renton, Onyx. "We plan to submit the data from the head and neck cancer studies to the U.S. Food and Drug Administration...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-12-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry